Related Experiment Video
Updated: Nov 22, 2025

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
Exploring gene knockout strategies to identify potential drug targets using genome-scale metabolic models
Abhijit Paul1, Rajat Anand1, Sonali Porey Karmakar1
1Complex Analysis Group, Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd milestone, Faridabad-Gurgaon Expressway, Faridabad, 121001, India.
Abstract:
Research on new cancer drugs is performed either through gene knockout studies or phenotypic screening of drugs in cancer cell-lines. Both of these approaches are costly and time-consuming. Computational framework, e.g., genome-scale metabolic models (GSMMs), could be a good alternative to find potential drug targets. The present study aims to investigate the applicability of gene knockout strategies to be used as the finding of drug targets using GSMMs. We performed single-gene knockout studies on existing GSMMs of the NCI-60 cell-lines obtained from 9 tissue types. The metabolic genes responsible for the growth of cancerous cells were identified and then ranked based on their cellular growth reduction. The possible growth reduction mechanisms, which matches with the gene knockout results, were described. Gene ranking was used to identify potential drug targets, which reduce the growth rate of cancer cells but not of the normal cells. The gene ranking results were also compared with existing shRNA screening data. The rank-correlation results for most of the cell-lines were not satisfactory for a single-gene knockout, but it played a significant role in deciding the activity of drug against cell proliferation, whereas multiple gene knockout analysis gave better correlation results. We validated our theoretical results experimentally and showed that the drugs mitotane and myxothiazol can inhibit the growth of at least four cell-lines of NCI-60 database.
Insights
Computational models offer a faster, cheaper way to find cancer drug targets. This study used genome-scale metabolic models (GSMMs) to predict gene targets, validating findings with drugs like mitotane.
Area of Science:
- Computational biology
- Cancer research
- Systems biology
Background:
- Traditional cancer drug discovery relies on costly and time-consuming gene knockout studies or phenotypic screening.
- Genome-scale metabolic models (GSMMs) present a promising computational alternative for identifying potential drug targets.
Purpose of the Study:
- To evaluate the effectiveness of gene knockout strategies using GSMMs for identifying novel cancer drug targets.
- To compare computational predictions with experimental data and existing screening results.
Main Methods:
- Performed single-gene knockout simulations on GSMMs of NCI-60 cancer cell lines from nine tissue types.
- Identified and ranked metabolic genes based on their impact on cancer cell growth reduction.
- Analyzed growth reduction mechanisms and compared gene ranking with shRNA screening data.
Main Results:
- Single-gene knockouts showed limited correlation with shRNA data but were significant for predicting drug activity against proliferation.
- Multiple gene knockout analyses yielded improved correlation results.
- Experimental validation confirmed that mitotane and myxothiazol inhibit the growth of at least four NCI-60 cell lines.
Conclusions:
- GSMM-based gene knockout strategies are valuable for predicting cancer drug targets, especially when considering multiple gene interactions.
- Computational approaches can guide experimental validation, accelerating the discovery of effective anti-cancer agents.
Related Concept Videos
In-vitro Mutagenesis
Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...

